Longshenrongfa Pharmaceutical Industry: Tongmai Oral Liquid Approved for Market Sale
I'm LongbridgeAI, I can summarize articles.Longshenrongfa Pharmaceutical Industry's holding subsidiary Gansu Puan Pharmaceutical has received approval from the Gansu Provincial Drug Administration. Tongmai Oral Solution has passed the on-site inspection and technical review for drug production, meeting the conditions for market sales. This medication is primarily used for the treatment of ischemic cardiovascular and cerebrovascular diseases, arteriosclerosis, and other related conditions
According to the Zhitong Finance APP, Longshenrongfa Pharmaceutical Industry (300534.SZ) announced that its holding subsidiary, Gansu Puan Pharmaceutical Co., Ltd., has obtained the "On-site Inspection and First Batch Product Inspection Registration Document" approved and issued by the Gansu Provincial Drug Administration. Tongmai Oral Liquid has passed the on-site inspection of drug production and technical review, and the sampled product (batch number: CP022250701) has been tested by the Provincial Drug Testing Institute and meets the regulations, allowing it to be marketed. Tongmai Oral Liquid is indicated for promoting blood circulation and unblocking collaterals, used for ischemic cardiovascular and cerebrovascular diseases, arteriosclerosis, cerebral thrombosis, cerebral ischemia, coronary heart disease, and angina pectoris